Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27797049 | 0.90 | ALOX5 (0.49) | ALOX5ADRB1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL28641840 | 0.90 | TLR2 (0.52) | ALOX5ADRB1ALDH1A1LMNAHTR3E | |
| SCHEMBL7415674 | 0.87 | TLR2 (0.55) | ALOX5ADRB1SMN1; SMN2LMNAHTR3E | |
| SCHEMBL3097713 | 0.86 | ALOX5 (0.60) | ALOX5ATMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10144997 | 0.86 | ALOX5 (0.60) | ALOX5ATMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8698788 | 0.85 | PLOD2 (0.56) | ALOX5ATMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2876503 | 0.85 | ADRB1 (0.59) | ADRB1ALDH1A1HTR3EHTR3BTP53 | |
| SCHEMBL8698430 | 0.84 | KMO (0.63) | ALOX5ATMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14881542 | 0.83 | ALOX5 (0.56) | ALOX5ATMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL62795 | 0.83 | HPGD (0.56) | ADRB1SMN1; SMN2ALDH1A1LMNAHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025015066-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024012554-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | 上海日馨医药科技股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2378878-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2004010942-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1313477-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
| EP-1210340-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2002-06-05 | — | — | EP | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-2002005819-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001014355-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| WO-1998002432-A1 | BICYCLIC COMPOUNDS FOR CONTROLLING MICTURITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | ALOX5 1543/4885ADRB1 158/4885ATM 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.